Worldwide ovarian cancer vaccine trial

Women whose ovarian cancer is in remission after surgery and/or chemotherapy are being sought to take part in a worldwide trial of a vaccine that may stop the disease returning.

The vaccine trial involves 800 women from Australia, America and Europe.

Earlier trials of the Australian-developed CVac™ vaccine indicate it is non-toxic and has no significant side effects.

For further information, email Neil Frazer at [email protected] or visit www.primabiomed.com.au

The National Breast and Ovarian Cancer Centre says ovarian cancer is the ninth most common cancer diagnosed in Australian women.
The number of woman diagnosed with ovarian cancer in Australia is on the rise. The number of woman increased from 833 in 1982 to 1,266 in 2007. It is estimated that 1,488 will be diagnosed with ovarian cancer in Australian in 2015.
One in 78 women will be diagnosed with ovarian cancer before the age of 85.
The risk of ovarian cancer is more common in older women.
The age-standardised incidence rate of ovarian cancer has decreased significantly. In 1982 the incidence rate was 12.4 compared with 10.8 in 2007.